| Bioactivity | Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. | ||||||||||||
| Invitro | Selumetinib (AZD6244) causes a time- and dose-dependent reduction in DNA synthesis and cell viability in primary, induces growth arrest and apoptosis associated with the inactivation of ERK in primary 2-1318 cells[1]. Selumetinib (AZD6244) (1µM) shows anti-proliferative effects through G0/G1 arrest on H-441, H-1437 cells[2]. Selumetinib (AZD6244) results in the growth inhibition of several cell lines containing B-Raf and Ras mutations but has no effect on a normal fibroblast cell line[3]. | ||||||||||||
| Name | Selumetinib | ||||||||||||
| CAS | 606143-52-6 | ||||||||||||
| Formula | C17H15BrClFN4O3 | ||||||||||||
| Molar Mass | 457.68 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Selumetinib
CAS: 606143-52-6 F: C17H15BrClFN4O3 W: 457.68
Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.